An immersive journey through advances in age-related macular degeneration — from subclinical detection to nutraceutical precision.
For years, AREDS2 formulations have been the standard of care for dry AMD. But emerging genetic research suggests that for some patients, these supplements may actually increase the risk of progressing to Wet AMD. Is it time to rethink the "one-size-fits-all" approach?Join us for a deep dive into the groundbreaking — and often controversial — research linking Complement Factor H, ARMS2, and AREDS formula efficacy.
A review of the original data and what it actually told us about Geographic Atrophy vs. Wet AMD.
Understanding Genotype Groups (GTG) 1, 2, 3, and 4. Why do GTG 2 patients show a statistically significant risk of harm from zinc?
Why does the AAO recommend against testing? A review of the statistical debates (0.632 Bootstrap, Validation Sets) and the financial interests regarding the AREDS patent.
New clinical data showing an Odds Ratio of 4.81 for developing Wet AMD based on genotype and supplement mismatch.
How to identify which patients may need AREDS without Zinc, and which patients derive the most benefit from standard AREDS2 formulations.
A comprehensive walkthrough of advances in AMD diagnosis and treatment — from choriocapillaris imaging to precision nutraceuticals.
10 questions · Must score 8/10 or higher to pass. COPE Activity XXXX · 1 CE Hour
Please fill in your details. This helps us maintain accurate CE records of who completes the quiz.
Your information is kept private and used only for CE record-keeping.
Contact Us
Having trouble with the course or quiz? Have a question? Send us a message and we'll get back to you.